Tranexamic Acid tablets recalled due to failed specification testing
AVKARE LLC is recalling Tranexamic Acid USP 650mg tablets nationwide due to failed quality control specifications for conductivity. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This FDA Class III recall involves a manufacturing specification failure with no reported illnesses or injuries. FDA Class III recalls are typically scored 1 or 2; the failed purity and degradation specifications merits classification as Moderate rather than Low.
Plain-English summary
AVKARE LLC is recalling Tranexamic Acid USP 650 mg tablets nationwide. The recall affects 592 cartons with Lot 44286 (expiration February 2025) distributed throughout the United States. The affected product is identified by NDC 50268-772-13.
The product failed specification testing for conductivity, which is a quality control measure for pharmaceutical purity and degradation. Testing results were out of specification, indicating the product does not meet published manufacturing standards.
No illnesses or injuries have been reported. Consumers who have obtained this product should stop using it and contact their healthcare provider or pharmacist for guidance.
The recalled product
- Product
- TRANEXAMIC ACID (TRANEXAMIC ACID)
- Brand
- TRANEXAMIC ACID
- Manufacturer
- AVKARE LLC
- Category
- Drug — Prescription Tablet
- Hazard
- impurities
- degradation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 44286 Exp. 02/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TRANEXAMIC ACID
- ModerateTranexamic Acid Tablets Recalled for Failed Manufacturing Specifications
FDA (Drugs) · 2023-06-21
- ModerateTranexamic Acid Injection Recalled Due to Metal Particulate Contamination
FDA (Drugs) · 2022-10-12
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27